Friday, September 29, 2023


Biotechnology News Magazine

Karen J. Wilson Appointed to the LAVA Therapeutics Board of Directors

Latest Posts

Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

Airway Therapeutics began recruiting patients on March 28, 2023, for daily treatment up to 7 days at the highest dose of zelpultide alfa (rhSP-D) following a Data Safety Monitoring Committee (DSMC) report of no safety concerns.

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.

PathO3Gen Solutions UVZone® Proven 99.9993% Effective Against Candida Auris: Shoes and Floors in Healthcare Facilities Should Be Addressed as Outbreak Continues

PathO3Gen Solutions’ multi-patented UVZone Shoe Sanitizing Stations, when placed in high-traffic and high-risk areas, enhance healthcare facility infection control measures, and may improve overall hospital biosafety.

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

Under the terms of Pharming's 2019 exclusive license agreement with Novartis for leniolisib, the corresponding first commercial sale of Joenja® triggers a $10 million milestone payment by Pharming to Novartis.

April 1, 2021

Karen J. Wilson brings more than three decades of finance and leadership experience in the life sciences industry.

“I am delighted to welcome Karen to our Board of Directors,” said Stephen Hurly, Lava Therapeutics Chief Executive Officer and President. “She joins us at an exciting time for our company as our first gamma-delta bsTCE candidates progress towards the clinic. Her deep experience leading finance organizations across both clinical- and commercial-stage public life science companies will be invaluable to LAVA as we advance our pipeline aimed at improving patient outcomes and creating value for our shareholders.”

Ms. Wilson is a biopharmaceutical finance executive and board member with experience in life science companies across finance, strategy, and risk management. She currently serves on the Board of Directors of Angion Biomedica, Connect Biopharma, and Vaxart, Inc. She was most recently Senior Vice President of Finance at Jazz Pharmaceuticals plc until September 2020 after serving as Vice President of Finance and Principal Accounting Officer.

Prior to joining Jazz Pharmaceuticals in February 2011, Ms. Wilson served as Vice President of Finance and Principal Accounting Officer at PDL BioPharma, Inc. She also previously served as a Principal at the consulting firm of Wilson Crisler LLC, Chief Financial Officer of ViroLogic, Inc., Chief Financial Officer and Vice President of Operations for Novare Surgical Systems, Inc., and as a consultant and auditor for Deloitte & Touche LLP.

Ms. Wilson is a Certified Public Accountant and received a B.S. in Business from the University of California, Berkeley.

“With two candidates expected to enter the clinic in 2021 following a successful IPO, I am thrilled to join LAVA’s Board,” Ms. Wilson said. “I am very excited about the potential of the LAVA platform to potentially transform the cancer treatment landscape. I look forward to working with the rest of the Board and management team to build on LAVA’s success and optimize the value of its unique gamma-delta T cell engager platform in oncology.”

Latest Posts

Learn More




Our Sister Publication

Medical Device News Magazine